Setmelanotide FDA approval date

The FDA approved Setmelanotide (IMCIVREE) on 25 Nov 2020.

FDA approval date
25 Nov 2020

Drug identity checked against registry records

Also recorded as IMCIVREE; Imcivree; RM-493; SET

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673RYTMPhase 2Completed2016-10-26Actual
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634RYTMPhase 3Completed2025-12-19Actual
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137RYTMPhase 2Completed2013-09-28Actual
Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240RYTMPhase 2Completed2022-06-28Actual
Long Term Extension Trial of SetmelanotideNCT03651765RYTMPhase 2, Phase 3Completed2025-01-09Actual
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546RYTMPhase 3Recruiting2027-03-13Estimated
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231RYTMPhase 2Completed2023-08-04Actual
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543RYTMPhase 2Completed2022-03-01Actual
A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597RYTMPhase 2Active not recruiting2026-11-03Actual
A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756RYTMPhase 3Active not recruiting2025-03-18Actual
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522RYTMPhase 3Completed2020-11-16Actual
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741RYTMPhase 3Completed2023-09-18Actual
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192RYTMPhase 3Completed2020-05-25Actual
Open-Label Extension Study of SetmelanotideNCT06596135RYTMPhase 3Completed2026-06-24Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-11-25DaySetmelanotideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA213793", "applicant_as_listed_by_fda": "RHYTHM", "brand_names": ["IMCIVREE"], "active_ingredients": ["SETMELANOTIDE ACETATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201125", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026